Browsing by Author Giugliano, Robert P

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 9 of 9
Issue DateTitleAuthor(s)Citation
2017Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialKeech, Anthony (Tony); De Ferrari, Gaetano M; Deedwania, Prakash; et al, Various; Giugliano, Robert P; Gouni-Berthold, Ioanna; Kuder, J; Leiter, Lawrence A.; Murphy, Sabina A.; Sabatine, Marc S.; Wiviott, S; NH&MRC Clinical Trials CentreCardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial, The Lancet Diabetes & Endocrinology, vol.5, 12, 2017,pp 941-950
2017Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trialKeech, Anthony (Tony); Ceska, Richard; De Ferrari, Gaetano M; et al, Various; Gaciong, Zbigniew A; Giugliano, Robert P; Gouni-Berthold, Ioanna; Lopez-Miranda, Jose; Park, Jeong-Gun; Pedersen, Terje R; Toth, Kalman; NH&MRC Clinical Trials CentreClinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial, The Lancet, vol.390, 10106, 2017,pp 1962-1971
2017Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: Secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trialKeech, Anthony (Tony); Ferreira, Jorge; Giugliano, Robert P; Huber, Kurt; Lewis, Basil S.; Murphy, S; Pedersen, T; Pineda, Armando Lira; Sabatine, Marc S.; Sever, Peter; Somaratne, Ransi; Tokgozoglu, S. Lale; NH&MRC Clinical Trials CentreClinical efficacy and safety of evolocumab in high-risk patients receiving a statin: Secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial, JAMA Cardiology, vol.2, 12, 2017,pp 1385-1391
2017Cognitive function in a randomized trial of evolocumabKeech, Anthony (Tony); Giugliano, Robert P; Honarpour, Narimon; Im, Kyungah; Kanevsky, Estella; Kurtz, C; Mach, Francois; Ott, Brian R.; Pedersen, Terje R; Robinson, Jennifer; Sabatine, Marc S.; Schneider, J; Sever, Peter; Wang, Huei; Wasserman, Scott M; Zavitz, Kenton H.; NH&MRC Clinical Trials CentreCognitive function in a randomized trial of evolocumab, New England Journal of Medicine, vol.377, 7, 2017,pp 633-643
2017Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular diseaseKeech, Anthony (Tony); Fonarow, Gregg; Giugliano, Robert P; Lindgren, Peter; Pedersen, Terje R; Qian, Yi; Sabatine, Marc S.; Sever, Peter; Somaratne, Ransi; van Hout, Ben; Villa, Guillermo; NH&MRC Clinical Trials CentreCost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease, JAMA Cardiology, vol.2, 10, 2017,pp 1069-1078
2017Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trialKeech, Anthony (Tony); Giugliano, Robert P; Honarpour, Narimon; Kurtz, C; Mach, Francois; Ott, Brian R.; Pedersen, T; Sabatine, Marc S.; Schneider, J; Sever, Peter; Wang, Huei; Wasserman, Scott M; Zavitz, Kenton H.; NH&MRC Clinical Trials CentreDesign and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial, Clinical Cardiology, vol.40, 2, 2017,pp 59-65
2014Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trialsSullivan, David; et al, Various; Giugliano, Robert P; Kim, Jae; Koren, Michael J; Raal, Frederick J; Roth, Eli M; Somaratne, Ransi; Stein, Evan; Wasserman, Scott M; Weiss, Robert; School of Public Health: NH&MRC Clinical Trials CentreEfficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials, European Heart Journal, vol.35, 33, 2014,pp 2249-2259
2017Evolocumab and clinical outcomes in patients with cardiovascular diseaseKeech, Anthony (Tony); et al, Various; Giugliano, Robert P; Honarpour, Narimon; Kuder, J; Liu, Thomas; Murphy, Sabina A.; Sabatine, Marc S.; Wang, Huei; Wasserman, Scott M; Wiviott, S; NH&MRC Clinical Trials CentreEvolocumab and clinical outcomes in patients with cardiovascular disease, New England Journal of Medicine, vol.376, 18, 2017,pp 1713-1722
2016Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trialKeech, Anthony (Tony); Giugliano, Robert P; Honarpour, Narimon; Liu, Thomas; Pedersen, Terje R; Sabatine, Marc S.; Scott, Rob; Sever, Peter; Wang, Huei; Wasserman, Scott M; NH&MRC Clinical Trials CentreRationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial, American Heart Journal, vol.173, N/A, 2016,pp 94-101